8-K: Nektar Therapeutics Q3 2026 Results: Increased R&D, Declining Revenue

Nektar Therapeutics reported third quarter 2026 financial results, showing a decrease in revenue and a substantial increase in operating costs, primarily driven by R&D investments for its lead drug candidate, rezpegaldesleukin.

Summary

• Nektar Therapeutics announced its financial results for the third quarter ended September 30, 2026.
• Revenue for Q3 2026 was $9.4 million, down from $11.8 million in Q3 2025. Revenue for the first nine months of 2026 was $30.4 million, down from $33.4 million in the same period of 2025.
• Total operating costs and expenses increased to $67.2 million in Q3 2026 from $43.5 million in Q3 2025. For the first nine months of 2026, costs rose to $169.6 million from $145.9 million in 2025.
• Research and Development (R&D) expenses significantly increased to $44.1 million in Q3 2026 from $27.3 million in Q3 2025, and to $118.9 million for the first nine months of 2026 from $87.6 million in 2025.
• General and Administrative (G&A) expenses increased to $24.6 million in Q3 2026 from $16.1 million in Q3 2025, but decreased for the first nine months of 2026.
• Net loss for Q3 2026 was $55.7 million ($1.63 per share), compared to a net loss of $35.5 million ($1.87 per share) in Q3 2025.
• Net loss for the first nine months of 2026 was $141.2 million ($4.60 per share), compared to $128.0 million ($8.14 per share) in the first nine months of 2025.
• Cash and investments totaled $952.9 million as of September 30, 2026, an increase from $245.8 million on December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to declining revenues and increasing operating costs, despite progress in Phase 3 development. The significant increase in R&D expenses is a key factor.

Positives

• Initiated all three global ZENITH AD registrational trials for rezpegaldesleukin in atopic dermatitis.
• The global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.
• Cash and investments increased significantly to $952.9 million as of September 30, 2026, from $245.8 million on December 31, 2025.
• Phase 2b REZOLVE-AD study met all primary and key secondary endpoints for rezpegaldesleukin.
• Data from the Phase 2b REZOLVE-AA study showed sustained efficacy and hair regrowth after treatment cessation.

Negatives

• Revenue decreased in Q3 2026 ($9.4M vs $11.8M) and for the first nine months of 2026 ($30.4M vs $33.4M).
• Total operating costs and expenses increased significantly in Q3 2026 ($67.2M vs $43.5M) and for the first nine months of 2026 ($169.6M vs $145.9M).
• Net loss widened in Q3 2026 to $55.7 million from $35.5 million in Q3 2025.
• Net loss per share for Q3 2026 was $1.63, a wider loss than the $1.87 per share in Q3 2025, despite a higher share count.

Risks

• Substantial risks exist for continued research and development, including negative safety and efficacy findings in future clinical studies.
• The risk of failure is high for drug candidates in preclinical and clinical development, with no assurance of regulatory approval.
• Data from ongoing clinical trials may be preliminary and subject to change.
• Clinical trial initiation or completion, and data availability, may be delayed or unsuccessful due to regulatory issues, patient enrollment, manufacturing challenges, or evolving requirements.
• Patents may not issue, may not be enforceable, or may require additional third-party licenses.
• The company faces risks and uncertainties described in its SEC filings, including its most recent Form 10-K.

Future Outlook

Topline data readouts for the rezpegaldesleukin Phase 3 program are expected in the summer of 2028, with the first Biologics License Application (BLA) filing targeted for 2029. The ZENITH AA trial is expected to begin in December 2026.

Management Comments

• "This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development."
• "We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned."
• "The strong body of clinical and translational data generated to-date for rezpegaldesleukin reinforce our conviction in its novel and differentiated Treg mechanism, which targets multiple inflammatory pathways that underpin chronic autoimmune disease."
• "We believe rezpegaldesleukin has the potential to offer an important new therapeutic approach for patients, and were focused on advancing to our topline data readouts in the summer of 2028 with the first BLA filing in 2029."

Industry Context

StockSavvy.ai notes that Nektar's increased R&D spending aligns with the typical investment required for advancing late-stage clinical trials in the competitive biotechnology sector, particularly for novel therapies targeting autoimmune and inflammatory diseases.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing.
• The company is advancing rezpegaldesleukin, a regulatory T cell stimulator, in Phase 3 trials for atopic dermatitis and alopecia areata, indicating a focus on novel mechanisms of action within the immunology space.

Stakeholder Impact

• Shareholders: Increased R&D spending and widening net loss may impact short-term investor sentiment, while progress in Phase 3 trials offers long-term potential.
• Employees: Continued investment in R&D suggests ongoing commitment to product development and potential future growth.
• Patients: Advancement of rezpegaldesleukin in Phase 3 trials offers potential for new therapeutic options for atopic dermatitis and alopecia areata.

Next Steps

• Advance rezpegaldesleukin through Phase 3 development for atopic dermatitis and alopecia areata.
• Initiate the global ZENITH AA registrational trial in alopecia areata in December 2026.
• Achieve topline data readouts for the ZENITH AD program in summer 2028.
• Target first BLA filing for rezpegaldesleukin in 2029.

Key Dates

Recommendation

The company is making significant progress in its Phase 3 trials for rezpegaldesleukin, which is a positive long-term indicator. However, the declining revenue, increasing operating costs, and widening net loss in the current quarter warrant caution. The substantial cash reserves provide a buffer, but the path to profitability and regulatory approval remains long and uncertain. Therefore, a 'hold' position is recommended pending further clinical data and financial performance.

Keywords

rezpegaldesleukin, atopic dermatitis, alopecia areata, Phase 3 trials, biotechnology, clinical development, financial results, R&D expenses